Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$9.14|
|52 Week High||US$7.39|
|52 Week Low||US$18.95|
|1 Month Change||3.16%|
|3 Month Change||0.66%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-45.11%|
Recent News & Updates
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Strong Position To Grow Its Business
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Longboard Pharmaceuticals EPS beats by $0.29
Longboard Pharmaceuticals (LBPH): Q1 GAAP EPS of -$0.84 beats by $0.29.Cash and cash equivalents balance of $120.9M.Press Release
|LBPH||US Pharmaceuticals||US Market|
Return vs Industry: Insufficient data to determine how LBPH performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LBPH performed against the US Market.
Stable Share Price: LBPH is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: LBPH's weekly volatility (7%) has been stable over the past year.
About the Company
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines for neurological diseases. Its products include LP352, a Phase I clinical trial product for the developmental and epileptic encephalopathies (DEEs) and refractory epilepsies; LP143, a product for amyotrophic lateral sclerosis and other neuroinflammatory disorders; and LP659, a product for multiple neuroinflammatory disorders. Longboard Pharmaceuticals, Inc. was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020.
Longboard Pharmaceuticals Fundamentals Summary
|LBPH fundamental statistics|
Is LBPH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|LBPH income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-1.47|
|Net Profit Margin||0.00%|
How did LBPH perform over the long term?See historical performance and comparison
Is Longboard Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate LBPH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate LBPH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: LBPH is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.
PE vs Market: LBPH is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate LBPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: LBPH is good value based on its PB Ratio (1.3x) compared to the US Pharmaceuticals industry average (3.2x).
How is Longboard Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: LBPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: LBPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: LBPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: LBPH is forecast to have no revenue next year.
High Growth Revenue: LBPH is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: LBPH is forecast to be unprofitable in 3 years.
How has Longboard Pharmaceuticals performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
Earnings and Revenue History
Quality Earnings: LBPH is currently unprofitable.
Growing Profit Margin: LBPH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if LBPH's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare LBPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LBPH is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).
Return on Equity
High ROE: LBPH has a negative Return on Equity (-21.57%), as it is currently unprofitable.
How is Longboard Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: LBPH's short term assets ($120.7M) exceed its short term liabilities ($3.3M).
Long Term Liabilities: LBPH has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: LBPH is debt free.
Reducing Debt: LBPH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: LBPH has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: LBPH has sufficient cash runway for 2.6 years if free cash flow continues to reduce at historical rates of 241.2% each year.
What is Longboard Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate LBPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate LBPH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if LBPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if LBPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of LBPH's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Kevin Lind (45 yo)
Mr. Kevin R. Lind serves as President and Chief Executive Officer at Longboard Pharmaceuticals, Inc. since March 2020 and also serves as its director since January 2020. Mr. Lind served as Chief Financial...
CEO Compensation Analysis
Compensation vs Market: Kevin's total compensation ($USD2.29M) is above average for companies of similar size in the US market ($USD1.08M).
Compensation vs Earnings: Insufficient data to compare Kevin's compensation with company performance.
Experienced Management: LBPH's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Experienced Board: LBPH's board of directors are not considered experienced ( 0.7 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: LBPH only recently listed within the past 12 months.
Longboard Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Longboard Pharmaceuticals, Inc.
- Ticker: LBPH
- Exchange: NasdaqGM
- Founded: 2020
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$157.348m
- Shares outstanding: 17.22m
- Website: https://www.longboardpharma.com
Number of Employees
- Longboard Pharmaceuticals, Inc.
- 6154 Nancy Ridge Drive
- San Diego
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/26 22:12|
|End of Day Share Price||2021/09/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.